Get the Stockscreener App
21.60
1.46%
-0.32
Inhibrx Biosciences Inc stock is traded at $21.60, with a volume of 58,806.
It is down -1.46% in the last 24 hours and up +47.24% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$21.92
Open:
$21.6
24h Volume:
58,806
Relative Volume:
0.54
Market Cap:
$312.68M
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.182
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
-6.41%
1M Performance:
+47.24%
6M Performance:
+59.06%
1Y Performance:
+48.25%
1-Day Range:
$21.37
$22.24
1-Week Range:
$21.37
$25.29
52-Week Range:
$10.80
$25.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
21.60 | 317.31M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
What’s the recovery path for long term holders of Inhibrx Biosciences Inc.Risk-Managed Trade Alerts for Consistency - Newser
Risk adjusted return profile for Inhibrx Biosciences Inc. analyzedIntraday Price Action Forecast Planner - Newser
Published on: 2025-08-01 16:27:04 - metal.it
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionShort Term Gain Strategy with AI Logic - Newser
Inhibrx Biosciences Inc. stock prediction for this weekQuick Profit Setup with Signal Forecast - Newser
What moving averages say about Inhibrx Biosciences Inc.Price Forecast Based on AI Analysis - Newser
When is Inhibrx Biosciences Inc. stock expected to show significant growthReal Time Strategy For Consistent Profits - jammulinksnews.com
Will Inhibrx Biosciences Inc. outperform the marketShort-Term Support and Resistance Forecast - Newser
Intrinsic Value of Inhibrx Biosciences Inc. Stock: Is It Undervalued or OvervaluedBuy Strategy with Smart Exit Timing - Newser
Tools to assess Inhibrx Biosciences Inc.’s risk profileEntry Timing with Downside Risk Analysis - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilityIn-Depth Stock Trading Volume Analysis - Newser
How does Inhibrx Biosciences Inc. compare to its industry peersFinancial News Tips To Watch Now - jammulinksnews.com
Sectors Driving Future Growth for Inhibrx Biosciences Inc. StockLong-Term Allocation Strategy Summary Breakdown - Newser
Reversal indicators forming on Inhibrx Biosciences Inc. stockEarly Entry Planner for Swing Candidates - Newser
Has Inhibrx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewTrade Flow Monitor with Volume Tracker - Newser
Should I hold or sell Inhibrx Biosciences Inc. stock in 2025Entry Signal Forecasts With Low Risk - jammulinksnews.com
New Product Launches: Will They Boost Inhibrx Biosciences Inc. Stock in 2025Real Trader Watchlist of Hot Stocks Released - metal.it
Is Inhibrx Biosciences Inc. Starting a New UptrendHigh Yield Stock Screening Results Explained - metal.it
Bollinger Bands Show Potential Breakout in Inhibrx Biosciences Inc.Oversold Recovery Opportunity Stocks Attract Buyers - metal.it
Inhibrx Biosciences Inc. Nearing Breakout Level After BounceInvestment Plan With Growth Optimization Finalized - metal.it
Inhibrx Biosciences Inc. Flashes Rebound Signal in Oversold ConditionAI Screening for Swing Trade Picks Finds Momentum - metal.it
Is Inhibrx Biosciences Inc. Forming a Consolidation BaseTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What makes Inhibrx Biosciences Inc. stock price move sharplyTechnical Screener for High Growth Stocks - Newser
Is Inhibrx Biosciences Inc. the Top Chart Pick This WeekHigh Accuracy Alerts for ROI Traders Detected - metal.it
Trend Reversal Possible in Inhibrx Biosciences Inc. Charts IndicateTechnical Stock Breakout Predictions Signal Entry Points - metal.it
How does Inhibrx Biosciences Inc. generate profit in a changing economyUnlock expert trading strategies for growth - jammulinksnews.com
What are Inhibrx Biosciences Inc. company’s key revenue driversMaster stock selection with insider knowledge - jammulinksnews.com
Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer - Insider Monkey
How strong is Inhibrx Biosciences Inc. company’s balance sheetGet exclusive access to premium stock research - jammulinksnews.com
Is Inhibrx Biosciences Inc. a growth stock or a value stockGame-changing capital returns - jammulinksnews.com
Inhibrx Biosciences Inc. stock trendline breakdownDividend Strategy Summary With 10-Year Outlook - Newser
Inhibrx Biosciences Inc. stock prediction for this week Technical Confirmation System with Signal Alerts - Newser
What are analysts’ price targets for Inhibrx Biosciences Inc. in the next 12 monthsHigh-velocity gains - jammulinksnews.com
What institutional investors are buying Inhibrx Biosciences Inc. stockAchieve breakthrough investment performance - jammulinksnews.com
Does Inhibrx Biosciences Inc. stock perform well during market downturnsUnlock exclusive trading strategies for gains - jammulinksnews.com
Published on: 2025-07-28 05:04:51 - jammulinksnews.com
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):